ACTION3 Phase 3 FSGS Clinical Study
The purpose of the ACTION3 study is to determine whether the investigational medication DMX-200 is effective and safe in treating a rare kidney condition called Focal Segmental Glomerulosclerosis (FSGS).
Find out moreProduct Pipeline
Dimerix develops new therapies through the clinic to commercialization. Our lead product is DMX-200 for FSGS kidney disease, currently in a Phase 3 clinical trial.
Find out more